Fate Therapeutics' iPSC-Derived Cell Therapies Induce Leukemic Blast Clearance, Show Durable Remissions In AML Patients

Fate Therapeutics Inc FATE has announced interim data from Phase 1 data from the Company's off-the-shelf, iPSC-derived natural killer (NK) cell programs in relapsed / refractory acute myeloid leukemia (AML).
Data come from two Phase 1 dose-escalation studies that are evaluating FT516 and FT538 as monotherapy.
As of the data cutoff date of April 16, five of 12 patients had achieved an objective response with complete leukemic blast clearance in the bone marrow.
Includes 3 complete remission with incomplete hematologic recovery (CRi), 1 morphologic leukemia-free state in FT516 (n=9) study and one CRi in FT538 (n=3) study.
Of the four patients achieving a CRi, one patient successfully proceeded to allogeneic stem cell transplant, and the other three patients remained on-study and in remission without further therapeutic intervention, two of whom remained in remission having been on-study for more than six months.
No dose-limiting toxicities, and no cases of any grade of cytokine release syndrome, immune effector cell-associated neurotoxicity syndrome, or graft-versus-host disease, were observed.
Price Action: FATE shares are up 1.45% at $72.55 in the premarket session on the last check Friday.